By Josh White
Date: Monday 19 May 2025
(Sharecast News) - Arecor Therapeutics announced on Monday that it has entered a formulation development partnership with Skye Bioscience to create an improved version of Skye's investigational obesity treatment, nimacimab.
By Josh White
Date: Wednesday 26 Mar 2025
(Sharecast News) - Arecor Therapeutics announced on Wednesday that it has entered into a new collaboration with a major global pharmaceutical company to apply its proprietary Arestat technology platform to develop an enhanced formulation of the partner's proprietary product.
By Josh White
Date: Monday 03 Feb 2025
(Sharecast News) - Arecor Therapeutics reported total full-year revenue of £5.1m in a trading update on Monday, up from £4.6m in 2023.
Currency | UK Pounds |
Share Price | 44.33p |
Change Today | 0.83p |
% Change | 1.92 % |
52 Week High | 159.00 |
52 Week Low | 38.00 |
Volume | 0 |
Shares Issued | 37.76m |
Market Cap | £16.74m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
CEO | Sarah Jennifer Howell |
CFO | David Ellam |
You are here: research